AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data
AstraZeneca has faced a series of disappointing late-stage trial results across cancer and rare diseases, including a failed Ultomiris trial in thrombotic microangiopathy after stem cell transplant and a failed Wainua trial for a rare heart condition.
The company also reported setbacks in key oncology programs such as Dato-DXd in lung cancer and camizestrant in breast cancer, while still posting solid overall growth driven by its oncology and rare disease franchises.
Market and analyst reaction has been cautious, with some concern over the company’s trial design and pipeline execution, though most maintain that AstraZeneca’s long-term growth story remains intact despite recent misses.
Sources:
AstraZeneca's rare disease drug misses main goal in late-stage trial
AstraZeneca's trial flop raises a bigger question
AstraZeneca Rare Disease Drug Disappoints in Advanced Study
AstraZeneca Shares Slide After Wainua Treatment Fails Heart Disease Trial
AstraZeneca reports first-half growth, disappointment in Ultomiris trial.
AstraZeneca drops MASH drug over disappointing phase 2 data
AstraZeneca lung cancer study fails in big setback for company
AstraZeneca, Daiichi Sankyo's Dato-DXd Fails to ...
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
Full-year-and-Q4-2024-results-announcement. ...
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
AstraZeneca Stock Falls After Disappointing Results in Breast Cancer Drug Trial
AstraZeneca 'magic' faces rare test after trial failure, share slide